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Abstract
Background: Germline genetic variation is associated with the differential expression of many
human genes. The phenotypic effects of this type of variation may be important when considering
susceptibility to common genetic diseases. Three regions at 8q24 have recently been identified to
independently confer risk of prostate cancer. Variation at 8q24 has also recently been associated
with risk of breast and colorectal cancer. However, none of the risk variants map at or relatively
close to known genes, with c-MYC mapping a few hundred kilobases distally.
Results:  This study identifies cis-regulators of germline c-MYC  expression in immortalized
lymphocytes of HapMap individuals. Quantitative analysis of c-MYC expression in normal prostate
tissues suggests an association between overexpression and variants in Region 1 of prostate cancer
risk. Somatic c-MYC  overexpression correlates with prostate cancer progression and more
aggressive tumor forms, which was also a pathological variable associated with Region 1. Expression
profiling analysis and modeling of transcriptional regulatory networks predicts a functional
association between MYC and the prostate tumor suppressor KLF6. Analysis of MYC/Myc-driven
cell transformation and tumorigenesis substantiates a model in which MYC overexpression
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promotes transformation by down-regulating KLF6. In this model, a feedback loop through E-
cadherin down-regulation causes further transactivation of c-MYC.
Conclusion: This study proposes that variation at putative 8q24 cis-regulator(s) of transcription
can significantly alter germline c-MYC expression levels and, thus, contribute to prostate cancer
susceptibility by down-regulating the prostate tumor suppressor KLF6 gene.
Background
Risk of human cancer associated with genetic variation at
chromosome 8q24 was first described for prostate cancer
in individuals with European ancestry and in African
Americans (Risk Region 1) [1,2]. This association was
stronger for more aggressive tumor forms [2-4] and for
earlier age at diagnosis in African Americans [1,5]. Differ-
ences in allele prevalences could account for the higher
incidence of prostate cancer in particular populations
such as African-Americans [1,2,5]. Subsequently, 8q24
has been associated with risk of prostate cancer by two
extra independent regions [6-8] and in risk of breast and
colorectal cancer by variation partially overlapping with
prostate cancer risk [9-13]. In particular, Haiman et al.[12]
first noted the existence of common risk variants for
breast and colorectal cancer at 8q24. These observations
suggest that multiple cancer genes may exist at 8q24 or,
alternatively, that risk variants converge on a common
biological mechanism [7].
In these studies risk variants did not map to known genes,
with few ESTs identified in relatively close proximity. A
proposed mechanism includes differences in genomic
structure that would make the 8q24 region more prone to
subsequent somatic amplification [14]. The c-MYC gene is
of particular interest in this region because its ectopic
expression has been shown to induce prostatic neoplasia
[15-17]. Here, we analyze genetic and genomic data to
provide evidence of 8q24 cis-regulator(s) of germline c-
MYC transcription. In addition, genomic data modeling
predicts a molecular mechanism linking germline c-MYC
overexpression and prostate tumorigenesis.
Results
Genetic association scan for germline expression 
differences
Scanning associations between genetic variation at 8q24
and c-MYC gene expression levels in immortalized lym-
phocytes of HapMap CEU (Utah residents with ancestry
from Northern and WesternEurope) and YRI (Yoruba in
Ibadan Nigeria) individuals showed the existence of clus-
ters of SNPs with nominal P values < 0.05 (Fig. 1). To
assess clustering significance, we examined the proportion
of significant SNPs in genomic windows 2- or 4-fold the
average size of linkage disequilibrium blocks in CEUs or
YRIs, respectively (~42 kb corresponding to ~66 SNPs in
CEUs and ~36 kb corresponding to ~61 SNPs in YRIs).
Twenty thousand permutations were performed to evalu-
ate the significance of the observed clustering. One
genomic region in CEUs and three regions in YRIs were
identified with high density of significant SNPs (Fig. 1).
Variation at the c-MYC locus was observed with a trend in
CEUs, which might suggest the existence of cis-regulators
in the gene structural elements (blue bar in Fig. 1A). Two
variants in this region (rs4645943 C and rs16902364 A)
are associated with germline differential expression of c-
MYC. The allele frequencies of these SNPs were reported
to differ between prostate cancer cases and controls in dif-
ferent populations (i.e. 87.7% (cases) and 77.7% (con-
trols) in Hawaiians; 96.3% (cases) and 95.1% (controls)
in CEUs for rs4645943 C) [7]. This observation warrants
further genetic analysis of the region with regard to pros-
tate cancer risk.
The scan revealed a possible association between variants
in Region 1 of prostate cancer risk and differential germ-
line expression of c-MYC  (Fig. 1B). Several significant
SNPs within this region were identified: the most signifi-
cant were rs7387447, rs10808558 and rs16902176 (P val-
ues < 0.01). The rs10808558 A allele showed an
association with c-MYC overexpression in YRIs (expres-
sion difference of 0.23 log2 units, 95% confidence interval
(CI) 0.06 – 0.41; P = 0.007) and this SNP is in low linkage
disequilibrium (LD) with the prostate cancer risk variant
rs1447295 (r2 = 0.19). Overall, the scan analysis suggests
the existence of 8q24 cis-regulators of germline c-MYC
transcription in lymphocytes, partially overlapping with
Region 1 of prostate cancer risk.
Expression differences in normal prostate tissues
Given the possible association of Region 1 variants with
germline  c-MYC  overexpression in immortalized lym-
phocytes of HapMap individuals, we next examined
expression differences in normal prostate tissues. For this
analysis we used 54 previously characterized normal pros-
tate tissue samples [18,19] and a real-time qRT-PCR pro-
tocol developed for prostate samples [20-22]. Genotyping
the prostate cancer-associated rs1447295 variant in these
samples identified six heterozygotes harboring the risk
allele A (CA genotypes). No significant age differences
were found between donors harboring the two different
genotypes (CA versus CC; no AA homozygotes were iden-
tified). Quantitative RT-PCR study using three gene refer-BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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Genetic association scan for germline c-MYC differential expression in CEUs and YRIs Figure 1
Genetic association scan for germline c-MYC differential expression in CEUs and YRIs. (A) Top panel shows results for individ-
ual SNPs and bottom panel shows results for significant SNP density in genomic windows of ~42 kb/~66 SNPs in CEUs. The 
red horizontal dashed line marks the nominal P value of 0.05. Variants associated with risk of breast [9], colorectal [10-13] or 
prostate [1-8, 24] cancer are marked with dashed lines as indicated in the inset. (B) Top panel shows results for individual SNPs 
and bottom panel shows results for significant SNP density in genomic windows of ~36 kb/~61 SNPs in YRIs. Linkage disequi-
librium (D'/LOD) plots are shown at the bottom for YRIs. Region 1 of prostate cancer risk is shown.BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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ences (18S, ALAS1 and TBP) identified significant c-MYC
overexpression in samples harboring the risk allele rela-
tive to CC homozygotes (n = 26) (Wilcoxon rank sum test
P = 0.004) (Fig. 2A). In addition, no evidence of allele-
specific amplification in tumors arising in CA individuals
was observed (not shown). These results suggest the
involvement of germline c-MYC overexpression in pros-
tate cancer susceptibility.
Germline copy number variants
As a possible mechanism explaining germline overexpres-
sion, we next examined copy number variants (CNVs) at
the c-MYC locus in CEUs and YRIs, and in 322 unrelated
individuals from the Spanish general population using a
multiplex ligation-dependent probe amplification
(MLPA) assay. This assay identified genomic gains at the
c-MYC locus at a relatively low frequency in the Spanish
general population (< 1%; 2/322) (Additional file 1).
However, analysis of rs1447295 genotypes in these indi-
viduals did not reveal association with the risk allele and,
importantly, none of the CEUs or YRIs showed CNVs with
this assay. Therefore, a CNV including c-MYC does not
seem to be a major contributor to the risk of prostate can-
cer and germline c-MYC overexpression associated with
Region 1. Wong et al.[23] previously described a CNV
including  c-MYC  but only with genomic losses. This
observation corroborates the structural complexity of
8q24 and opens the possibility that different genomic
configurations are associated with risk alleles in Region 1
or other 8q24 regions.
Gene expression analysis in prostate tumors
Since Region 1 variants were associated with earlier age at
diagnosis and high Gleason scores or aggressive tumor
forms [1-8,24], we examined the expression level of 8q24
genes in primary prostate tumors and their association
with clinical and pathological variables. For these analy-
ses, we used a publicly available expression data set con-
taining different prostate cellular populations isolated
using laser-capture microdissection [25].
Comparison of normal versus neoplastic samples showed
differential expression of c-MYC  (Fig. 2B). Specifically,
overexpression appears in the more advanced stages of
tumorigenesis such as carcinomas and hormone-refrac-
tory metastases (t-test P < 10-3). Tomlins et al.[25] previ-
ously noted the identification of c-MYC  in an
"overexpressed in progression" signature. The FAM84B
gene at 8q24 also shows overexpression but mainly at ear-
lier stages (P = 0.043 and P = 0.002 for intraepithelial neo-
plasia and carcinomas, respectively), which suggests that
FAM84B could also be a target of 8q24 somatic amplifica-
tion. Analysis of Gleason scores showed a trend for c-MYC
overexpression (ANOVA test P = 0.056) (Fig. 2C). Associ-
ation between c-MYC  overexpression and high-grade
prostate tumors was previously noted by Buttyan et al.[26]
and Fleming et al.[27]. These observations point to a
causal relationship between somatic c-MYC overexpres-
sion and the more aggressive forms of prostate tumors.
Expression profiles and modeling of transcriptional 
regulatory networks
Transcriptional targets of MYC include many genes that
were identified as conferring risk of prostate cancer and/or
being somatically mutated in prostate tumors [28,29]. We
sought to identify which of these genes, particularly those
conferring risk of prostate cancer, could be functionally
associated with c-MYC  by examining the similarity
between expression profiles using a data set containing 50
normal tissues and 52 prostate tumors [30]. This analysis
revealed strong correlations between c-MYC and the pros-
tate tumor suppressor Kruppel-like factor 6 (KLF6) gene
(Fig. 3A). Correlations were positive for c-MYC microarray
probes 1973_s_at and 37724_at (Pearson's correlation
coefficient (PCC) = 0.65; P  < 10-13) and negative for
1827_s_at (PCC = -0.71; P < 10-15). Extensive alternative
splicing of the c-MYC mRNA could account for this differ-
ence [31].
To determine the molecular consequence of the predicted
MYC-KLF6 functional association, we generated models
of transcriptional regulatory networks in prostate tissues.
Using the ARACNe algorithm [32] and the 102 hybridiza-
tions of Singh et al.[30], we identified 88 and 111 putative
transcriptional targets of MYC and KLF6 in this cell type,
respectively (Fig. 3B). The intersection of these two sets
contains 25 genes, which is a much larger number of
genes than randomly expected using simulations of equiv-
alent gene sets (empirical P < 0.001). Importantly, 16 of
these genes contain MYC binding sites at their promoters
based on TRANSFAC (eukaryotes transcription factors
database) matrices [33]. In addition, many known MYC
targets [29] were also identified: 22 out of 88 (25%) and
23 out of 111 (20%) of the MYC and KLF6 predicted tran-
scriptional targets, respectively (Fig. 3B). Notably, c-MYC
and KLF6 were also directly connected and the KLF6 pro-
moter contains three predicted binding sites for MYC (not
shown). A 5-gene recurrence predictor of prostate cancer
[34] contains KLF6, three common ARACNe-based pre-
dictions between MYC and KLF6 (FOS, JUNB and ZFP36),
and PPFIA3, which is functionally related to another pre-
dicted target of KLF6 (PPFIBP2) (Fig. 3B). These observa-
tions further support the role of KLF6, c-MYC  and the
ARACNe-based predictions in prostate tumorigenesis.
Comparison of ARACNe-based predictions with the Tom-
lins et al. data set [25] identified 13 of the 88 predicted
MYC transcriptional targets differentially expressed
between normal prostate tissues and androgen-independ-
ent metastases (FDR-adjusted P values < 0.05). In addi-BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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Analysis of c-MYC expression in normal and prostate cancer tissues Figure 2
Analysis of c-MYC expression in normal and prostate cancer tissues. (A) Relative expression differences of c-MYC calculated 
using three gene references with the following formula: R = Fc-MYC - (FTBP - FALAS1) where Fgene i= Ctgene i - Ct18 S. (B) c-MYC expres-
sion in prostate cancer progression. Mean expression values are marked by a red solid rhombus. (C) c-MYC expression associ-
ation study with Gleason scores.BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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Expression profiling and modeling of transcriptional regulatory networks Figure 3
Expression profiling and modeling of transcriptional regulatory networks. (A) Transcriptional profiles of c-MYC and KLF6 in 
prostate tissues [30] using U95A Affymetrix probes shown in the inset. (B) Integrated transcriptional regulatory networks of 
MYC and KLF6. Gene function assignment based on GO term annotations and known MYC transcription targets are shown as 
indicated in the inset.BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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tion, 20 of the predicted targets were found to be
differentially expressed between normal prostate tissues
and adenocarcinomas. Notably, ~46–40% of these genes
(6/13 and 8/20) were also predicted to be direct transcrip-
tional targets of KLF6 by the ARACNe algorithm, which
endorses the putative functional association between
MYC and KLF6.
Analysis of MYC/Myc-driven cellular transformation and 
tumorigenesis
To evaluate the functional significance of the predicted
shared MYC/KLF6 transcriptional targets, we examined
expression data derived from a model of MYC-driven cel-
lular transformation of quiescent human mammary epi-
thelial cells and from MMTV-Myc-driven mammary
tumors in mice [35,36]. Of the 25 predicted common tar-
gets, 16 (64%) were found to be differentially expressed in
cell transformation of quiescent human mammary epi-
thelial cells (Fig. 4A). This proportion is ~2-fold higher
than expected by chance taking into account all genes
examined in the microarray platform (χ2-test P = 0.004),
which substantiates the identification of true MYC targets.
Moreover, 11 of the 16 genes contain MYC binding sites
at their promoters. Importantly, KLF6 was also identified
and showed strong down-regulation in this model (t-test
P values < 10-3) (Fig. 4A).
Analysis of MMTV-Myc-driven mammary tumors in mice
showed consistent results with the analysis of quiescent
human mammary epithelial cells. Twelve differentially
expressed genes were detected, eight of which coincided
with the human genes mentioned above (Fig. 4B). Genes
that did not overlap between the two studies showed sim-
ilar trends, for example the human TGIF showed a trend
for down-regulation (P = 0.067) while it was identified as
significant in the study of mice tumors (P  = 0.007).
Importantly, this analysis also revealed Klf6 down-regula-
tion (P = 0.003) (Fig. 4B). Overall, the discovery of KLF6/
Klf6 down-regulation in two different models of MYC/
Myc-driven cell transformation supports the hypothesis
that c-MYC germline overexpression could act as a risk fac-
tor for prostate cancer by converging on a molecular
mechanism such as the functional inactivation of the
KLF6 gene or gene product.
Using the MYC/Myc-driven cell transformation models,
we next examined the differential expression of known
KLF6 transcriptional targets of relevance to epithelial can-
cers, E-cadherin (CDH1 gene) [37] and p21 (CDKN1A)
[38]. This analysis revealed strong down-regulation of
CDH1 in the transformation of quiescent human mam-
mary epithelial cells (P values < 10-5) and a trend in the
model of Myc-driven mice tumorigenesis (P = 0.088). No
significant differences were appreciable for CDKN1A or
Cdkn1a. These observations suggest that KLF6 down-regu-
lation mediated by germline MYC overexpression could
promote epithelial neoplasia by down-regulating E-cad-
herin.
Discussion
Combined analysis of genetic and expression data facili-
tates the identification of transcriptional regulators acting
in any part of the genome [39,40]. Examination of differ-
ent ethnic groups reinforces the identification of these reg-
ulators but also reveals differences between populations
[41,42]. Due to their functional and structural complexity,
transcriptional regulators are largely undercharacterized.
However, it is thought that their genetic variability may be
relevant when considering susceptibility to common dis-
eases. Specifically, their causal relationship to cancer is
almost unknown since most genetic analyses have been
focused on coding regions. Insights into differential germ-
line gene expression and tumorigenesis have been gained
mainly from mice models, such as the overexpression of
the RAS family of genes [43], Mad2 [44] or c-MYC [45,46].
This study analyzed the hypothesis that variation at 8q24
cis-regulator(s) of transcription could significantly alter
germline c-MYC expression levels and, thus, contribute to
cancer susceptibility. Although the genetic scanning anal-
ysis performed is susceptible to false positives, the exist-
ence of true cis-regulator(s) is suggested by the
identification of clusters of significant SNPs. Although
larger sample series are required to draw definitive conclu-
sions, the quantitative analysis of geneexpression in nor-
mal prostate tissues supports the model of c-MYC
overexpression associated with Region 1 of prostate can-
cer risk. Tissue-specific cis-regulator(s) that correlate with
additional cancer risk regions at 8q24 may also exist. In a
recent study it was noted that tissue specificity is a critical
factor in the transcriptional responsiveness of MYC targets
[47].
The 8q24 region appears amplified in up to 50% of pros-
tate tumors and c-MYC is thought to be the primary target
of these amplifications since it is overexpressed in prostate
hyperplasia and neoplasia [25]. Ectopic overexpression of
c-MYC/c-Myc is sufficient to immortalize human prostate
epithelial cells [17] and has been shown to generate
human-like prostate tumors in mice [16]. In addition, c-
MYC  overexpression in prostate cancer cells enables
androgen-independent growth [48]. These observations
lead to suggestions of a dual role for c-MYC in prostate
cancer. At early stages it would promote proliferation
while at later stages it would facilitate androgen-inde-
pendent growth [17]. Our study further proposes that
germline  c-MYC  overexpression may promote cellular
transformation of the normal epithelium and, by exten-
sion, risk of prostate cancer by down-regulating the pros-
tate tumor suppressor KLF6  gene. This model isBMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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Expression analysis of predicted MYC/KLF6 transcriptional targets in MYC/Myc-driven cell transformation and tumorigenesis Figure 4
Expression analysis of predicted MYC/KLF6 transcriptional targets in MYC/Myc-driven cell transformation and tumorigenesis. 
(A) Results of the analysis of quiescent human mammary epithelial cells [36]. (B) Results of the analysis of MMTV-Myc-driven 
tumors in mice [35]. Genes (red, up-regulated; green, down-regulated), corresponding microarray probes and two-tailed t-test 
P values are shown.BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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hypothetical and mainly based on the application of the
ARACNe algorithm, which achieves a reasonable tradeoff
between true- and false-positive rates by eliminating the
majority of indirect interactions inferred from gene co-
expression [49,50]. Experimental corroboration of the
predictions generated in this study is therefore needed,
particularly in prostate tissues or cell lines.
The KLF6 gene is inactivated in prostate cancer by loss of
heterozygosity and/or by somatic mutations identified in
tumors, cell lines and xenografts [51]. Recent evidence has
extended the role of KLF6 inactivation to several other
neoplastic processes as esophageal carcinomas [52],
glioblastomas [53], head and neck squamous cell carcino-
mas [54], hepatocellular carcinomas [55], non-small cell
lung cancer [56], ovarian carcinomas [57] and particu-
larly, with regard to 8q24 risk variants, to colorectal cancer
[58]. A key KLF6 transcriptional target for epithelial neo-
plasia is E-cadherin (CDH1 gene), which is a suppressor
of cellular invasion [37]. KLF6 directly transactivates the
CDH1 promoter resulting in increased levels of its gene
product [37]. CDH1  is genetically inactivated in many
human cancers and shows reduced or absent expression
in approximately 50% of prostate tumors [59], playing a
critical role in the transition from a noninvasive to an
invasive phenotype [60]. Notably, it has recently been
proposed that EphB receptors act as tumor suppressors of
colorectal cancer, and possibly breast and prostate cancer,
through an E-cadherin-mediated mechanism that com-
partmentalizes tumor cells in the initial stages of tumori-
genesis [61]. Loss of E-cadherin can result in β-catenin
nuclear localization and, as a result, the up-regulation of
LEF/TCF-mediated transcriptional targets such as c-
MYC[62]. Overall, our study suggests the existence of a
transcriptional regulatory circuit that is perturbed in
human cancer and which begins with the germline over-
expression of c-MYC, causing down-regulation of KLF6
which then reduces the transactivation of CDH1, which in
turns feeds c-MYC expression through β-catenin and LEF/
TCF transcriptional complex activation.
Variants at 8q24 have been associated with risk of pros-
tate, breast and colorectal cancer [1-13,24,63]. Although
there are different blocks of linkage disequilibrium that
harbor risk variants, cancer clustering might suggests the
existence of a common molecular mechanism of suscepti-
bility. Expression analyses in normal prostate, breast and
colorectal tissues and examination of association with
genotypes are needed to determine the convergence on a
common mechanism. Nonetheless, tumor tissue specifi-
city may show dependences on specific, although not
fully understood, mechanisms of neoplasia. The ectopic
overexpression of MYC/Myc in specific cell types of mice
promotes breast or prostate tumorigenesis [16,45,64],
while widespread expression produces different types of
tumors but with preferential appearance of specific epi-
thelial and non-epithelial origins [46]. Overexpression of
c-MYC also constitutes an early event after loss of the APC
tumor suppressor gene that initiates colorectal cancer
[62,65]. In addition, recent evidence shows that loss of
heterozygosity at the KLF6 locus contributes to the transi-
tion from the compartmentalized carcinoma to the inva-
sive carcinoma, specifically in sporadic colorectal cancer
[66,67], which might suggest a link with the mechanism
of tumor-cells compartmentalization in the initial stages
of tumorigenesis mediated by E-cadherin [61]. Although
the predictions generated in this study should be treated
with a degree of caution, these observations would agree
with the hypothesis of a cancer susceptibility mechanism
mediated by c-MYC germlineoverexpression.
Conclusion
This study proposes that variation at putative 8q24 cis-reg-
ulator(s) of transcription can significantly alter germline
c-MYC expression levels and, thus, contribute to prostate
cancer susceptibility by down-regulating the prostate
tumor suppressor KLF6  gene. We propose a transcrip-
tional regulatory model perturbed in human cancer with
a feedback loop for c-MYC.
Methods
Genetic association analysis
We analyzed HapMap genotypes and paired expression
data recently made available for immortalized lym-
phocytes from four ethnic groups and including 210 inde-
pendent individuals in total (60 Utah residents with
ancestry from northern and western Europe; 45 Han Chi-
nese in Beijing; 45 Japanese in Tokyo; and 60 Yoruba in
Ibadan Nigeria; Gene Expression Omnibus (GEO) record
GSE6536) [42]. Transcriptional differences were scanned
between the 128 and 129 Mb of chromosome 8, corre-
sponding to ~1,530 SNPs (NCBI build 35). Scans were
performed in R with the SNPassoc package [68]. The log-
additive effects of alleles were examined. Association of
genotypes with the variable response (gene expression
level) was calculated by fitting linear equations and P val-
ues obtained by assessing the change in deviance against
the null model. Association analysis between genotypes,
downloaded from the HapMap data release 21a, and gene
expression levels were performed using the web-software
SNPStats [69]. The D'/LOD plots were generated using the
Haploview software [70].
Microarray gene expression analysis
Using the HapMap lymphocyte expression data [42] and
the prostate cancer data of Tomlins et al.[25], matrix series
were downloaded from GEO references GSE6536 and
GSE6099, respectively. Using the Singh et al.[30] raw data,
background correction, normalization and averaging of
expression values were performed with the robust multi-BMC Genomics 2008, 9:12 http://www.biomedcentral.com/1471-2164/9/12
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array average (RMA) algorithm. ARACNe Java [49,50] was
used to model the gene expression regulatory networks of
c-MYC and KLF6. In this analysis, data processing inequal-
ity (DPI) tolerance was set to 0.20 and the mutual infor-
mation (MI) threshold was 0.05. Normalized data sets of
MYC/Myc-driven cellular transformation and tumorigen-
esis were downloaded from the GEO records GSE3151
and GSE3158 [35,36]. Gene probes were matched using
the NetAffx (Affymetrix) tool and differentially expressed
probes were identified by calculating two-tailed t-test P
values.
Genotyping and quantitative RT-PCR analyses
Prostate tissue specimens were collected through the
Tumor Bank of the Bellvitge University Hospital and the
Catalan Institute of Oncology. Genotyping of rs1447295
was performed by direct sequencing of PCR products of
genomic DNA using the following forward and reverse
primers, respectively: 5'-GAGTTGCACGCCAGACACTA-3'
and 5'-TTTCCCATACCCCATTCTGA-3'. Quantitative RT-
PCR analysis of c-MYC was performed using a protocol
previously developed with the LightCycler™ DNA Master
SYBR Green I Kit (Roche Applied Sciences) [20-22] and c-
MYC  primers 5'-CAGCTGCTTAGACGCTGGATT-3' and
5'-GTAGAAATACGGCTGCACCGA-3', and TBP  primers
5'-GAACCACGGCACTGATTTTC-3' and 5'-CACAGCTC-
CCCACCATATTC-3'. Relative expression differences were
calculated using three gene references (18S, ALAS1 and
TBP) with the following formula: R = Fc-MYC - (FTBP - FALAS1)
where Fgene i = Ctgene i - Ct18 S.
Copy number variant analysis
MLPA assays were performed following the conventional
protocol with 150 ng of DNA, overnight ligation and 32
cycles of PCR. Probes for c-MYC  were 5'-
GGGTTCCCTAAGGGTTGGAGGAGGAAC-
GAGCTAAAACGGAGCT-3' and 5'P-
TTTTTGCCCTGCGTGACCAGATCCTCTAGATT-
GGATCTTGCTGGCAC-3'.
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